Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Regeneron Pharmaceuticals Receives Dupixent Approval in Japan

April 12, 2025
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has recently received approval for its drug Dupixent in Japan. Despite this positive news, the company's stock, symbol REGN on NasdaqGS, has dropped 10% over the last week. However, experts from Stocks Prognosis recommend considering the long-term potential of Regeneron Pharmaceuticals' stock movement before making any investment decisions. The company's innovative approach to drug development and its recent success in obtaining regulatory approvals make it a promising player in the pharmaceutical industry.
If you want to leave a comment, then you need Login or Register





Other data for REGN

Related data

REGNJuly 5, 2025Regeneron Pharmaceuticals: Revolutionizing Healthcare with Innovative Drug Approvals  ~1 min.

Regeneron Pharmaceuticals, Inc. recently made headlines with the approval of Dupixent by the US FDA, in collaboration with Sanofi....


REGNJune 27, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors as UBS Lowers Price Target  ~1 min.

Regeneron Pharmaceuticals Inc. has been making waves in the biotech industry, with impressive financial and operating results....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit  ~2 min.

REGENERON PHARMACEUTICALS, INC. (REGN) has successfully reached the price target forecast set by QuantWave, resulting in a profit of 27.18%....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 26.25%  ~1 min.

REGENERON PHARMACEUTICALS, INC. stock recently achieved the price target forecast set by QuantWave on March 21, 2025. The forecast indicated a short direction, with the stock price at $657....


REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....


REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target Forecast, Bringing 27.31% Profit  ~1 min.

On March 4, 2025, QuantWave, the automated forecasting platform, issued a short signal for REGENERON PHARMACEUTICALS, INC. stock when it was trading at $674.49....


REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits 29.73% Profit Target as Forecasted by QuantWave  ~1 min.

REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) achieved a significant milestone as it hit the price target forecasted by QuantWave, providing investors with a profit of 29.73%....


REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Short Forecast Target with 17.43% Profit  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on July 1, 2022, predicted a short direction with a price of $593.76....


REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 21.51% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecast set by QuantWave, resulting in a profitable outcome for investors....


REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Forecast Target with a Profit of 30.6%  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecasted by QuantWave, resulting in a profit of 30.6% for investors who followed the short signal....


REGNFebruary 3, 2025Regeneron Pharmaceuticals Inc. Receives Positive Analyst Recommendations  ~1 min.

Regeneron Pharmaceuticals Inc. (REGN) has recently received bullish recommendations from leading analysts, indicating a positive outlook for the company's future....


REGNJanuary 24, 2025Regeneron Pharmaceuticals, Inc. Announces Positive Results from Clinical Trial of its Breakthrough Drug  ~1 min.

Regeneron Pharmaceuticals, Inc., a leading biotechnology company, has recently announced positive results from a clinical trial of its groundbreaking drug....


REGNFebruary 13, 2025Analyst Cuts Regeneron Pharmaceuticals REGN Price Target After Sales Concerns and Investor Lawsuit Hagens Berman  ~2 min.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) faced a setback as an industry analyst recently cut the company's price target....


REGNAugust 13, 2024REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 14.62%  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully achieved the price target forecast as predicted by QuantWave's automated forecasting platform....


REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Short Forecast Target with 17.43% Profit  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on July 1, 2022, predicted a short direction with a price of $593.76....